Phase 3 Peripheral Arterial Disease Trial, Recruiting NCT07560306 Sponsor: Brigham and Women's Hospital Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Phase 3 Peripheral Arterial Disease Trial, Recruiting

NCT07560306
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to give written consent to participate in the study
  • People who have been diagnosed with amyloid cardiomyopathy (a heart condition caused by abnormal protein build-up)
  • People who have a history of atrial fibrillation or atrial flutter (irregular heart rhythms)
  • People who have had a specific heart imaging test (called a TEE, which looks inside the heart) within the past 14 days, under certain conditions related to their blood-thinning medication (confirm with trial site)
  • People who have a TEE heart imaging test already scheduled within the next 14 days

Who may not be able to join:

  • People who have electrical implants in their body, such as a pacemaker, defibrillator, or brain stimulator
  • People who are pregnant or breastfeeding (a pregnancy test is required for women who could become pregnant before joining)
  • People who experience severe anxiety in enclosed spaces (claustrophobia)
  • People whose radiation exposure from research-related procedures in the past 12 months has already reached the department's safety limit (50 mSv)
  • People who are unable to lie still on a flat bed inside a PET/MR scanner
  • People who are directly or indirectly supervised by the main researchers leading the trial
  • People who weigh more than 300 pounds, due to the scanner table's weight limit
  • People who have metal or electrical implants that are not safe for use in a PET/MR scanner
  • People who have had a stroke, heart attack, or major heart or other surgery within the past 3 months
  • People who have previously had a procedure to close off or remove part of the heart called the left atrial appendage, or who have a device in place to block it
  • People who have fainted or lost consciousness within the past 6 weeks
  • People whose heart rate is consistently above 120 or below 50 beats per minute
  • People who have pauses in their heartbeat lasting more than 3 seconds during the day
  • People who have not had a standard heart ultrasound (echocardiogram) within the past 6 months
  • People who are not able to give written consent to participate
  • People whom the trial investigators determine are not suitable for the study for clinical or safety reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 6172335860

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
7 July 2026
Est. completion
30 March 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Intracardiac Thrombus

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov